Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Hypotension 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 5Nivolumab 3Biopsy 3Magnetic Resonance Spectroscopy 2Docetaxel 2talazoparib 1romidepsin 1pembrolizumab 1olaparib 1imisopasem manganese 1gallium 68 PSMA-11 1durvalumab 1balstilimab 1aldesleukin 1abivertinib 1abiraterone 1abarelix 1Watchful Waiting 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Observation 1N-acetylcochinol-O-phosphate 1Mental Status and Dementia Tests 1Menogaril 1Magnetic Resonance Imaging 1Ketones 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × imisopasem manganese × Genitourinary × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡